Skip to main content
Clinical Trials/NCT03367091
NCT03367091
Terminated
Not Applicable

Energy Consumption and Cardiorespiratory Load During Overground Gait Training With a Wearable Exoskeleton After Stroke: the Effect of the Level of Swing Assistance

Vrije Universiteit Brussel1 site in 1 country1 target enrollmentJuly 9, 2018
ConditionsStroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
Vrije Universiteit Brussel
Enrollment
1
Locations
1
Primary Endpoint
Net heart rate (HR, beats/min) at minute 10 of walking
Status
Terminated
Last Updated
7 years ago

Overview

Brief Summary

To investigate acute metabolic and cardiorespiratory responses during overground gait training with a wearable exoskeleton in persons after stroke

Detailed Description

RESEARCH AIMS: * To investigate the effect of the level of swing assistance on the acute metabolic and cardiorespiratory responses during overground gait training with a wearable exoskeleton in persons after stroke * To investigate if there is an interaction-effect between the level of swing assistance and the duration of walking * To compare the exercise intensity to aerobic training recommendations STUDY DESIGN: An experimental, 1-group trial with randomized crossover design. PATIENT RECRUITMENT: Participants will be recruited at the AZ Herentals (Herentals, Belgium). LOCATION: The trial will be conducted at the REVAlution Center (Herentals, Belgium). ELIGIBILITY CRITERIA: See section "Eligibility" PROCEDURES: Before the start of the study, informed consent and baseline patient characteristics will be collected. Next, participants will be measured during three training sessions with the Ekso GT SmartAssist: * 20-minute training with high swing assistance * 20-minute training with neutral swing assistance * 20-minute training with high swing resistance Trainings will be performed on a separate day in a randomized order (within one week and controlled for time of day). Following settings will be used in all three conditions: sitting program ("Min lean"); standing program ("Auto lean"); step initiation program ("ProStep+"), training mode ("Off"), SmartAssist option ("2Free"); and stance support ("Low"). The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side. During training, participants will walk back and forth at a self-selected walking speed in a 30m hall way using a cane at the non-affected side. Prior to the experimental conditions, participants will have had three training sessions in the Ekso GT. RESTRICTIONS \& PROHIBITIONS: Participants will be instructed to not consume food, alcohol, caffeine or nicotine at least 3h prior to the intervention. Usual medication intake will be allowed with small amounts of water. MATERIALS: The Ekso GT robotic exoskeleton with SmartAssist (Ekso Bionics Inc., USA) will be used during the overground training sessions. A flexible facemask (adult facemask, small/medium, Cortex, Germany), lightweight chest carrying gas analysis system (Metamax 3B, Cortex, Germany) and Bluetooth heart rate belt (Polar H7, Polar Electro, Finland) will be used to measure metabolic and cardiorespiratory parameters. At the start of each measurement, gas (room air and reference gas (17.4% O2 and 5.1% CO2)) and volume (3L syringe) calibrations of the breath-by-breath gas analysis system will be performed in accordance with the manufacturer's instructions. OUTCOMES: See section "Outcome Measures" DATA-ANALYSES: Descriptive statistics will be calculated for baseline patient characteristics. To investigate the effect of level of swing assistance and duration, a repeated measures ANOVA (within factor duration and within factor assistance level) will be conducted (interaction-effect time x duration, main effect assistance level and main effect duration). In case of significant differences, posthoc analyses will be interpreted. The walking speed will be considered as a covariate in the ANOVA analysis (in case significant different between conditions). Significance level will be set at 5%.

Registry
clinicaltrials.gov
Start Date
July 9, 2018
End Date
December 31, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nina Lefeber

Doctoral Researcher

Vrije Universiteit Brussel

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Net heart rate (HR, beats/min) at minute 10 of walking

Time Frame: Minute 10 of 20-minute walking period

Heart rate during walking (beats/min) minus resting heart rate

Net minute ventilation (VE, L/min) at minute 15 of walking

Time Frame: Minute 15 of 20-minute walking period

The amount of air in- or exhaled per minute (L/min) during walking minus during rest

Net oxygen cost (OC, ml/kg/m) at minute 5 of walking

Time Frame: Minute 5 of 20-minute walking period

Net oxygen consumption (oxygen consumption (ml/kg/min) during walking minus during rest) divided by the walking speed (m/min)

Net oxygen cost (OC, ml/kg/m) at minute 10 of walking

Time Frame: Minute 10 of 20-minute walking period

Net oxygen consumption (oxygen consumption (ml/kg/min) during walking minus during rest) divided by the walking speed (m/min)

Net oxygen cost (OC, ml/kg/m) at minute 15 of walking

Time Frame: Minute 15 of 20-minute walking period

Net oxygen consumption (oxygen consumption (ml/kg/min) during walking minus during rest) divided by the walking speed (m/min)

Net minute ventilation (VE, L/min) at minute 5 of walking

Time Frame: Minute 5 of 20-minute walking period

The amount of air in- or exhaled per minute (L/min) during walking minus during rest

Net oxygen cost (OC, ml/kg/m) at minute 20 of walking

Time Frame: Minute 20 of 20-minute walking period

Net oxygen consumption (oxygen consumption (ml/kg/min) during walking minus during rest) divided by the walking speed (m/min)

Net heart rate (HR, beats/min) at minute 5 of walking

Time Frame: Minute 5 of 20-minute walking period

Heart rate during walking (beats/min) minus resting heart rate

Net heart rate (HR, beats/min) at minute 15 of walking

Time Frame: Minute 15 of 20-minute walking period

Heart rate during walking (beats/min) minus resting heart rate

Net heart rate (HR, beats/min) at minute 20 of walking

Time Frame: Minute 20 of 20-minute walking period

Heart rate during walking (beats/min) minus resting heart rate

Net minute ventilation (VE, L/min) at minute 10 of walking

Time Frame: Minute 10 of 20-minute walking period

The amount of air in- or exhaled per minute (L/min) during walking minus during rest

Net minute ventilation (VE, L/min) at minute 20 of walking

Time Frame: Minute 20 of 20-minute walking period

The amount of air in- or exhaled per minute (L/min) during walking minus during rest

Secondary Outcomes

  • Net Rating of Perceived Exertion (RPE, 6-20) at minute 5 of walking(Minute 5 of 20-minute walking period)
  • Percentage maximal heart rate (%HRmax) at minute 10 of walking(Minute 10 of 20-minute walking period)
  • Percentage heart rate reserve (%HRR) at minute 20 of walking(Minute 20 of 20-minute walking period)
  • Net Rating of Perceived Exertion (RPE, 6-20) at minute 10 of walking(Minute 10 of 20-minute walking period)
  • Net Rating of Perceived Exertion (RPE, 6-20) at minute 20 of walking(Minute 20 of 20-minute walking period)
  • Percentage maximal heart rate (%HRmax) at minute 20 of walking(Minute 20 of 20-minute walking period)
  • Metabolic Equivalent of Task (MET) at minute 10 of walking(Minute 10 of 20-minute walking period)
  • Percentage maximal heart rate (%HRmax) at minute 15 of walking(Minute 15 of 20-minute walking period)
  • Metabolic Equivalent of Task (MET) at minute 20 of walking(Minute 20 of 20-minute walking period)
  • Net Rating of Perceived Exertion (RPE, 6-20) at minute 15 of walking(Minute 15 of 20-minute walking period)
  • Percentage heart rate reserve (%HRR) at minute 15 of walking(Minute 15 of 20-minute walking period)
  • Metabolic Equivalent of Task (MET) at minute 5 of walking(Minute 5 of 20-minute walking period)
  • Percentage maximal heart rate (%HRmax) at minute 5 of walking(Minute 5 of 20-minute walking period)
  • Percentage heart rate reserve (%HRR) at minute 5 of walking(Minute 5 of 20-minute walking period)
  • Percentage heart rate reserve (%HRR) at minute 10 of walking(Minute 10 of 20-minute walking period)
  • Metabolic Equivalent of Task (MET) at minute 15 of walking(Minute 15 of 20-minute walking period)

Study Sites (1)

Loading locations...

Similar Trials